Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00655655 · ClinicalTrials.gov registry record · Phase 1
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
A Phase 1 study of Recurrent Melanoma and Insulinoma, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT00655655: Completed Phase 1 study of Recurrent Melanoma and Insulinoma, sponsored by Mayo Clinic.
NCT00655655 is a Phase 1 study of Recurrent Melanoma and Insulinoma that has completed, run by Mayo Clinic. The registered enrollment target is 96 participants, below the 169-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00655655, a Phase 1 study of Recurrent Melanoma and Insulinoma, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving everolimus together with vatalanib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus and vatalanib in treating patients with advanced solid tumors.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG everolimus
- PROCEDURE dynamic contrast-enhanced magnetic resonance imaging
- DRUG vatalanib
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2004-12 |
| Est. Completion | 2018-01-11 |
| Phase | Phase 1 |
What the finished NCT00655655 record still lists
NCT00655655 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 169-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (43% lower).
The record links to 10 conditions, with Recurrent Melanoma appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00655655 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00655655 about?
NCT00655655 is a clinical study titled "Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors". RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving everolimus together with vatalanib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and be...
What is the current status of trial NCT00655655?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2004-12. Estimated completion is 2018-01-11.
What conditions does trial NCT00655655 study?
This clinical trial studies the following conditions: Recurrent Melanoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Gastrinoma, Glucagonoma.
What interventions are being tested in trial NCT00655655?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), everolimus (DRUG), dynamic contrast-enhanced magnetic resonance imaging (PROCEDURE), vatalanib (DRUG).
Who is sponsoring clinical trial NCT00655655?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00655655 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00655655's enrollment target sits among peer trials
96 6th of 23 higher than 18 of 23 other Recurrent Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
RECRUITING · Phase 1
-
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
ACTIVE NOT RECRUITING · Phase 1
-
Decitabine in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
COMPLETED · Phase 1
-
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia